DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-005409-38-ES (EUCTR)	19/04/2013	29/01/2013	First study to test the validity of the treatment of the disease called idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with a drug called cotrimoxazole.	Pilot study phase III to evaluate the efficacy and safety of Trimethoprim-sulfamethoxazole in the treatment of idiopathic pulmonary fibrosis	Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis. MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Parasitic Diseases [C03]	Trade Name: SEPTRIN INN or Proposed INN: TRIMETHOPRIM Other descriptive name: TRIMETHOPRIM INN or Proposed INN: SULFAMETHOXAZOLE	Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)	NULL	Not Recruiting			Female: yes Male: yes	56	Phase 3	Spain
2	EUCTR2007-002324-15-GB (EUCTR)	04/09/2007	17/03/2008	The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia - TIPAC	The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia - TIPAC	Idiopathic Interstitial Pneumonia MedDRA version: 9.1;Level: LLT;Classification code 10022619;Term: Interstitial pulmonary fibrosis	Trade Name: Septrin Product Name: co-trimoxazole Product Code: N/A INN or Proposed INN: N/A Other descriptive name: CO-TRIMOXAZOLE	University of East Anglia	NULL	Not Recruiting			Female: yes Male: yes			United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2012-005409-38-ES
(EUCTR)

19/04/2013

29/01/2013

First study to test the validity of the treatment of the disease called idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with a drug called cotrimoxazole.

Pilot study phase III to evaluate the efficacy and safety of Trimethoprim-sulfamethoxazole in the treatment of idiopathic pulmonary fibrosis

Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis.
MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Parasitic Diseases [C03]

Trade Name: SEPTRIN
INN or Proposed INN: TRIMETHOPRIM
Other descriptive name: TRIMETHOPRIM
INN or Proposed INN: SULFAMETHOXAZOLE

Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

Spain

EUCTR2007-002324-15-GB
(EUCTR)

04/09/2007

17/03/2008

The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia - TIPAC

Idiopathic Interstitial Pneumonia
MedDRA version: 9.1;Level: LLT;Classification code 10022619;Term: Interstitial pulmonary fibrosis

Trade Name: Septrin
Product Name: co-trimoxazole
Product Code: N/A
INN or Proposed INN: N/A
Other descriptive name: CO-TRIMOXAZOLE

University of East Anglia

NULL

Not Recruiting

Female: yes
Male: yes

United Kingdom